Kura Oncology KURA 深 沪
等待开盘 11-11 09:30:00 美东时间
7.57
0.000
0.00%
华盛通- 最 高7.86
- 今 开7.57
- 成交量 250.23万股
- 最 低 7.29
- 昨 收 7.57
- 总市值 6.73亿
- 52周最高 13.90
- 市盈率 静 --
- 换手率 2.81%
- 52周最低 6.75
- 委 比 -20.63%
- 总股本 8896.06万
- 历史最高 43.00
- 量 比 0.69
- 振 幅 7.53%
- 历史最低 2.50
- 每 手 1
- 风险率 1.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kura Oncology Inc收平，成交额1882.43万美元
11月11日，Kura Oncology Inc（KURA）收平，报7.57美元，成交额1882.43万美元，市值6.73亿美元。 行情数据 • 开盘价：7....
今天 06:55
Kura Oncology Files Shelf Prospectus For Offering; Size Not Disclosed
Kura Oncology Files Shelf Prospectus For Offering; Size Not Disclosed
今天 06:22
Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
Kura Oncology reported strong Q3 2026 performance with KOMZIFTI net product revenue up 53% to $13.9M, new patient starts up 30%, and total prescriptions up 65%. KOMZIFTI maintained majority share in the R/R NPM1-m AML market. The company advanced ziftomenib into frontline AML and reached FDA alignment on a darlifarnib registrational study for HRAS-mutant salivary gland cancer. Financially, Kura has $492.1M in cash and secured up to $300M addition...
11-10 21:02
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology granted inducement stock options to three new employees under its 2023 Inducement Option Plan. The options, totaling 55,500 shares with an exercise price of $9.79 per share, vest over four years, with 25% vesting after one year and the remainder vesting monthly over the next 36 months. The grant aligns with Nasdaq Listing Rule 5635(c)(4).
11-06 12:30
Kura Oncology Inc收跌22.98%，成交额6710.41万美元
11月5日，Kura Oncology Inc（KURA）收跌22.98%，报7.61美元，成交额6710.41万美元，市值6.77亿美元。 行情数据 • 开盘...
11-05 06:57
MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors
MacroGenics, Inc. announced the appointment of Emil Kuriakose, M.D. and Michael Vasconcelles, M.D. as independent directors to its Board of Directors, effective October 30, 2026. Both bring extensive oncology drug development experience, which will support the company's pipeline advancement and long-term strategic goals. Dr. Kuriakose has over a decade of experience in oncology and metabolic disease drug development, most recently as Chief Medica...
11-03 21:05
Kura Oncology to Report Third Quarter Financial Results on November 10
Kura Oncology announced it will report third quarter 2026 financial results after market close on November 10, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update. The live webcast and archived replay will be available on the Company’s website. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer, with a pipeline targeting c...
11-03 11:58
Kura Oncology Inc收涨8.28%，成交额2392.15万美元
10月29日，Kura Oncology Inc（KURA）收涨8.28%，报10.72美元，成交额2392.15万美元，市值9.54亿美元。 行情数据 • 开...
10-29 05:46
Kura Oncology Inc收涨0.1%，成交额834.46万美元
10月27日，Kura Oncology Inc（KURA）收涨0.1%，报9.62美元，成交额834.46万美元，市值8.56亿美元。 行情数据 • 开盘价...
10-27 05:50
Kura Oncology Inc收跌6.39%，成交额1655.52万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:53
